sufentanil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
opioid receptor agonists, analgesics, fentanyl derivatives	2491	56030-54-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: sulfentanyl sulfentanil sulfentanil citrate sufentanil sufentanil citrate	An opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. Molecular weight: 386.55 Formula: C22H30N2O2S CLOGP: 3.59 LIPINSKI: 0 HAC: 4 HDO: 0 TPSA: 32.78 ALOGS: -4.51 ROTB: 8 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

sulfentanyl
sulfentanil
sulfentanil citrate
sufentanil
sufentanil citrate

An opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent.

Molecular weight: 386.55
Formula: C22H30N2O2S
CLOGP: 3.59
LIPINSKI: 0
HAC: 4
HDO: 0
TPSA: 32.78
ALOGS: -4.51
ROTB: 8

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	6 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.06 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	0 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	9.40 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	15 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.08 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	14 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
May 4, 1984	FDA	AKORN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	1435.28	29.26	356	5695	19799	50579274
Hypotension	271.93	29.26	224	5827	235245	50363828
Bronchospasm	253.94	29.26	87	5964	14767	50584306
Exposure during pregnancy	147.12	29.26	119	5932	120896	50478177
Maternal exposure during delivery	135.77	29.26	30	6021	976	50598097
Anaphylactic reaction	133.26	29.26	82	5969	53973	50545100
Cardiac arrest	122.71	29.26	92	5959	83559	50515514
Anaphylactoid shock	111.67	29.26	21	6030	297	50598776
Tachycardia	106.35	29.26	91	5960	99672	50499401
Circulatory collapse	101.55	29.26	49	6002	19951	50579122
Shock	76.79	29.26	41	6010	20609	50578464
Oliguria	73.62	29.26	30	6021	8186	50590887
Hepatocellular injury	70.66	29.26	42	6009	25905	50573168
Stress cardiomyopathy	67.95	29.26	28	6023	7859	50591214
Delayed recovery from anaesthesia	67.08	29.26	16	6035	733	50598340
Ventricular fibrillation	66.37	29.26	30	6021	10529	50588544
Mixed liver injury	65.93	29.26	22	6029	3429	50595644
Respiratory depression	65.74	29.26	31	6020	11979	50587094
Hepatorenal failure	65.16	29.26	15	6036	588	50598485
Eosinophilia	63.68	29.26	35	6016	18617	50580456
Cardio-respiratory arrest	63.20	29.26	52	5999	53840	50545233
Myoclonus	60.26	29.26	31	6020	14439	50584634
Peripheral nerve injury	59.86	29.26	13	6038	389	50598684
Fatigue	58.23	29.26	8	6043	707593	49891480
Haemodynamic instability	57.51	29.26	25	6026	7999	50591074
Spinal epidural haemorrhage	56.36	29.26	10	6041	100	50598973
Suspected product quality issue	56.21	29.26	11	6040	194	50598879
Hypocapnia	55.99	29.26	12	6039	337	50598736
Multiple organ dysfunction syndrome	53.70	29.26	46	6005	50291	50548782
Type I hypersensitivity	52.80	29.26	17	6034	2368	50596705
Bradycardia	51.37	29.26	50	6001	64376	50534697
Rash maculo-papular	49.77	29.26	34	6017	26607	50572466
Erythema	49.00	29.26	73	5978	146341	50452732
Unwanted awareness during anaesthesia	46.86	29.26	10	6041	275	50598798
Patent ductus arteriosus	44.97	29.26	17	6034	3803	50595270
Serotonin syndrome	44.89	29.26	31	6020	24682	50574391
Hyperlactacidaemia	40.54	29.26	14	6037	2419	50596654
Myoglobin blood increased	40.39	29.26	12	6039	1281	50597792
Cholestasis	39.53	29.26	29	6022	25372	50573701
Oxygen saturation decreased	39.17	29.26	46	6005	73202	50525871
Metabolic acidosis	38.41	29.26	34	6017	38791	50560282
Paralysis	37.34	29.26	19	6032	8645	50590428
Cauda equina syndrome	37.19	29.26	10	6041	744	50598329
Uterine hypotonus	37.08	29.26	7	6044	101	50598972
Anaesthetic complication	36.95	29.26	12	6039	1718	50597355
Postpartum haemorrhage	36.78	29.26	12	6039	1742	50597331
Acute generalised exanthematous pustulosis	36.78	29.26	19	6032	8919	50590154
Epidural haemorrhage	36.01	29.26	7	6044	119	50598954
Post procedural stroke	34.29	29.26	6	6045	55	50599018
Mydriasis	33.69	29.26	19	6032	10608	50588465
Foetal growth restriction	32.90	29.26	16	6035	6611	50592462
Anticholinergic syndrome	32.53	29.26	11	6040	1784	50597289
Torsade de pointes	31.79	29.26	19	6032	11816	50587257
Carcinoid crisis	31.78	29.26	7	6044	224	50598849
Foetal exposure during pregnancy	31.21	29.26	26	6025	27333	50571740
Suspected product contamination	31.21	29.26	5	6046	25	50599048
Diarrhoea	30.91	29.26	16	6035	588460	50010613
Foetal heart rate abnormal	30.83	29.26	8	6043	518	50598555
Haemodilution	29.99	29.26	6	6045	119	50598954
Toxic encephalopathy	29.45	29.26	14	6037	5501	50593572

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	879.99	31.37	236	4548	13100	29556643
Bronchospasm	164.78	31.37	61	4723	9548	29560195
Hypertransaminasaemia	129.86	31.37	40	4744	3566	29566177
Hyperthermia malignant	123.80	31.37	33	4751	1751	29567992
Hypotension	117.32	31.37	150	4634	194204	29375539
Anaphylactic reaction	113.99	31.37	65	4719	27508	29542235
Rash maculo-papular	94.35	31.37	55	4729	24234	29545509
Toxic epidermal necrolysis	86.47	31.37	47	4737	18106	29551637
Circulatory collapse	82.48	31.37	46	4738	18627	29551116
Drug reaction with eosinophilia and systemic symptoms	82.16	31.37	53	4731	27939	29541804
Tachycardia	78.27	31.37	76	4708	72334	29497409
Eosinophilia	72.61	31.37	45	4739	22116	29547627
Rhabdomyolysis	64.13	31.37	63	4721	60745	29508998
Haemodynamic instability	56.16	31.37	27	4757	8046	29561697
Septic shock	55.39	31.37	59	4725	62501	29507242
Shock	51.87	31.37	36	4748	21368	29548375
Injury	50.82	31.37	34	4750	19012	29550731
Hepatic cytolysis	49.37	31.37	25	4759	8322	29561421
Multiple organ dysfunction syndrome	48.04	31.37	55	4729	63061	29506682
Hepatorenal failure	47.38	31.37	12	4772	519	29569224
Cholestasis	46.65	31.37	35	4749	23427	29546316
Anaphylactoid shock	46.42	31.37	11	4773	359	29569384
Victim of crime	46.34	31.37	11	4773	362	29569381
Rash morbilliform	43.32	31.37	16	4768	2477	29567266
Erythema	43.17	31.37	57	4727	75549	29494194
Hepatocellular injury	42.93	31.37	32	4752	21211	29548532
Stress cardiomyopathy	41.94	31.37	14	4770	1610	29568133
Patent ductus arteriosus	39.78	31.37	16	4768	3115	29566628
Type I hypersensitivity	39.03	31.37	12	4772	1060	29568683
Suspected product quality issue	38.80	31.37	8	4776	135	29569608
Suspected product contamination	38.11	31.37	7	4777	62	29569681
Infantile apnoea	36.91	31.37	11	4773	874	29568869
Coma	36.29	31.37	38	4746	39412	29530331
Fear	35.48	31.37	21	4763	9483	29560260
Symmetrical drug-related intertriginous and flexural exanthema	35.05	31.37	8	4776	221	29569522
Fibrinolysis increased	32.53	31.37	5	4779	12	29569731
Post procedural haemorrhage	31.81	31.37	18	4766	7473	29562270
Anaesthetic complication	31.55	31.37	10	4774	976	29568767

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	2255.23	26.17	585	9473	29743	64458931
Bronchospasm	404.37	26.17	145	9913	21537	64467137
Hypotension	251.42	26.17	302	9756	380672	64108002
Anaphylactic reaction	247.07	26.17	146	9912	68518	64420156
Tachycardia	176.25	26.17	162	9896	149417	64339257
Circulatory collapse	168.34	26.17	89	9969	33643	64455031
Anaphylactoid shock	141.98	26.17	31	10027	723	64487951
Hyperthermia malignant	137.11	26.17	38	10020	2421	64486253
Hypertransaminasaemia	129.80	26.17	47	10011	7144	64481530
Cardiac arrest	126.17	26.17	137	9921	153927	64334747
Maternal exposure during delivery	126.10	26.17	29	10029	861	64487813
Rash maculo-papular	118.77	26.17	80	9978	46946	64441728
Shock	118.56	26.17	74	9984	38166	64450508
Eosinophilia	113.82	26.17	72	9986	38004	64450670
Hepatorenal failure	108.09	26.17	27	10031	1145	64487529
Toxic epidermal necrolysis	105.43	26.17	68	9990	37098	64451576
Drug reaction with eosinophilia and systemic symptoms	104.01	26.17	78	9980	54139	64434535
Hepatocellular injury	102.53	26.17	72	9986	45163	64443511
Stress cardiomyopathy	101.09	26.17	42	10016	9215	64479459
Suspected product quality issue	96.91	26.17	19	10039	255	64488419
Erythema	87.99	26.17	126	9932	186944	64301730
Type I hypersensitivity	86.20	26.17	29	10029	3545	64485129
Multiple organ dysfunction syndrome	84.34	26.17	91	9967	101322	64387352
Fatigue	82.75	26.17	10	10048	748720	63739954
Delayed recovery from anaesthesia	82.37	26.17	23	10035	1505	64487169
Cholestasis	80.41	26.17	62	9996	44810	64443864
Respiratory depression	79.35	26.17	48	10010	23395	64465279
Haemodynamic instability	79.06	26.17	41	10017	14871	64473803
Oliguria	71.36	26.17	38	10020	14538	64474136
Rhabdomyolysis	68.81	26.17	78	9980	91648	64397026
Suspected product contamination	68.51	26.17	12	10046	82	64488592
Septic shock	66.42	26.17	82	9976	105355	64383319
Mixed liver injury	63.68	26.17	26	10032	5455	64483219
Anaesthetic complication	62.49	26.17	21	10037	2558	64486116
Rash morbilliform	61.83	26.17	25	10033	5116	64483558
Cardio-respiratory arrest	61.13	26.17	76	9982	98317	64390357
Hepatic cytolysis	53.37	26.17	31	10027	14018	64474656
Myoclonus	52.32	26.17	38	10020	25080	64463594
Ventricular fibrillation	51.77	26.17	37	10021	23823	64464851
Bradycardia	51.68	26.17	77	9981	118142	64370532
Symmetrical drug-related intertriginous and flexural exanthema	50.80	26.17	13	10045	608	64488066
Peripheral nerve injury	50.49	26.17	13	10045	623	64488051
Diarrhoea	47.49	26.17	27	10031	722677	63765997
Torsade de pointes	47.32	26.17	31	10027	17332	64471342
Hypocapnia	46.55	26.17	12	10046	578	64488096
Coma	45.55	26.17	62	9996	87553	64401121
Acute pulmonary oedema	45.34	26.17	27	10031	12782	64475892
Victim of crime	45.25	26.17	11	10047	416	64488258
Carcinoid crisis	44.58	26.17	11	10047	443	64488231
Dizziness	44.44	26.17	7	10051	430156	64058518
Spinal epidural haemorrhage	44.37	26.17	9	10049	145	64488529
Oxygen saturation decreased	44.27	26.17	68	9990	107108	64381566
Unwanted awareness during anaesthesia	44.21	26.17	10	10048	275	64488399
Fibrinolysis increased	43.73	26.17	7	10051	25	64488649
Headache	42.21	26.17	15	10043	529452	63959222
Neuromuscular block prolonged	40.56	26.17	12	10046	965	64487709
Ventricular tachycardia	39.99	26.17	37	10021	34228	64454446
Fear	38.60	26.17	29	10029	20142	64468532
Fall	38.36	26.17	9	10049	416817	64071857
Uterine hypotonus	36.98	26.17	7	10051	77	64488597
Altered state of consciousness	36.82	26.17	37	10021	37865	64450809
Hyperlactacidaemia	36.70	26.17	17	10041	4827	64483847
Dermatitis bullous	36.50	26.17	23	10035	12031	64476643
Postpartum haemorrhage	35.92	26.17	12	10046	1435	64487239
Tonic clonic movements	35.88	26.17	13	10045	1976	64486698
Acute generalised exanthematous pustulosis	35.65	26.17	24	10034	14034	64474640
Device issue	35.62	26.17	29	10029	22619	64466055
Nervous system disorder	35.15	26.17	29	10029	23049	64465625
Cauda equina syndrome	34.92	26.17	11	10047	1092	64487582
Foetal heart rate abnormal	34.45	26.17	8	10050	248	64488426
Renal injury	33.63	26.17	24	10034	15405	64473269
Exposure during pregnancy	33.07	26.17	50	10008	77625	64411049
Injury	32.76	26.17	42	10016	55950	64432724
Malaise	31.94	26.17	11	10047	396236	64092438
Epidural haemorrhage	31.66	26.17	7	10051	173	64488501
Respiratory acidosis	30.33	26.17	19	10039	9836	64478838
Leukocytosis	29.82	26.17	33	10025	37707	64450967
Mydriasis	29.26	26.17	22	10036	15290	64473384
Metabolic acidosis	29.25	26.17	45	10013	70913	64417761
Post procedural stroke	29.00	26.17	6	10052	107	64488567
Cough	28.84	26.17	6	10052	302142	64186532
Cardiogenic shock	28.50	26.17	30	10028	32397	64456277
Myoglobin blood increased	28.43	26.17	12	10046	2735	64485939
Vasoplegia syndrome	28.34	26.17	12	10046	2755	64485919
Anaphylactoid reaction	27.93	26.17	14	10044	4724	64483950
Haemodilution	27.47	26.17	6	10052	140	64488534
Third stage postpartum haemorrhage	27.40	26.17	4	10054	6	64488668
Arthralgia	26.92	26.17	18	10040	442242	64046432
Hypercapnia	26.66	26.17	16	10042	7678	64480996
Post procedural haemorrhage	26.32	26.17	19	10039	12412	64476262

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N01AH03	NERVOUS SYSTEM ANESTHETICS ANESTHETICS, GENERAL Opioid anesthetics
CHEBI has role	CHEBI:35482	narcotic analgesic
CHEBI has role	CHEBI:38877	intravenous anesthetics
CHEBI has role	CHEBI:55322	mu-opioid agonists
CHEBI has role	CHEBI:60807	anaesthestic adjuvant
FDA MoA	N0000175684	Full Opioid Agonists
FDA EPC	N0000175690	Opioid Agonist
MeSH PA	D000759	Adjuvants, Anesthesia
MeSH PA	D000700	Analgesics
MeSH PA	D000701	Analgesics, Opioid
MeSH PA	D000777	Anesthetics
MeSH PA	D018686	Anesthetics, Intravenous
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D009294	Narcotics
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D018689	Sensory System Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
General anesthesia	indication	50697003
Postoperative pain	indication	213299007
Asthenia	contraindication	13791008
Chronic disease of respiratory system	contraindication	17097001
Decreased cardiac function	contraindication	43650005
Bradycardia	contraindication	48867003
Injury of head	contraindication	82271004
Kidney disease	contraindication	90708001	DOID:557
Disease of liver	contraindication	235856003	DOID:409

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.37	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 0.03MG BASE	DSUVIA	ACELRX PHARMS	N209128	Nov. 2, 2018	RX	TABLET	SUBLINGUAL	10245228	Jan. 5, 2027	TREATMENT OF ACUTE PAIN
EQ 0.03MG BASE	DSUVIA	ACELRX PHARMS	N209128	Nov. 2, 2018	RX	TABLET	SUBLINGUAL	10507180	Jan. 5, 2027	TREATMENT OF ACUTE PAIN
EQ 0.03MG BASE	DSUVIA	ACELRX PHARMS	N209128	Nov. 2, 2018	RX	TABLET	SUBLINGUAL	8226978	Jan. 5, 2027	TREATMENT OF ACUTE PAIN
EQ 0.03MG BASE	DSUVIA	ACELRX PHARMS	N209128	Nov. 2, 2018	RX	TABLET	SUBLINGUAL	8535714	Jan. 5, 2027	TREATMENT OF ACUTE PAIN
EQ 0.03MG BASE	DSUVIA	ACELRX PHARMS	N209128	Nov. 2, 2018	RX	TABLET	SUBLINGUAL	8778393	Jan. 5, 2027	TREATMENT OF ACUTE PAIN
EQ 0.03MG BASE	DSUVIA	ACELRX PHARMS	N209128	Nov. 2, 2018	RX	TABLET	SUBLINGUAL	8778394	Jan. 5, 2027	TREATMENT OF ACUTE PAIN
EQ 0.03MG BASE	DSUVIA	ACELRX PHARMS	N209128	Nov. 2, 2018	RX	TABLET	SUBLINGUAL	8865211	Jan. 5, 2027	TREATMENT OF ACUTE PAIN
EQ 0.03MG BASE	DSUVIA	ACELRX PHARMS	N209128	Nov. 2, 2018	RX	TABLET	SUBLINGUAL	9320710	Jan. 5, 2027	TREATMENT OF ACUTE PAIN
EQ 0.03MG BASE	DSUVIA	ACELRX PHARMS	N209128	Nov. 2, 2018	RX	TABLET	SUBLINGUAL	8202535	Oct. 22, 2030	TREATMENT OF ACUTE PAIN
EQ 0.03MG BASE	DSUVIA	ACELRX PHARMS	N209128	Nov. 2, 2018	RX	TABLET	SUBLINGUAL	8865743	Oct. 22, 2030	TREATMENT OF ACUTE PAIN

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Mu-type opioid receptor	GPCR	P35372	OPRM_HUMAN	AGONIST	EC50	8.13	WOMBAT-PK	CHEMBL
Kappa-type opioid receptor	GPCR	P41145	OPRK_HUMAN		EC50	6.70	WOMBAT-PK
Delta-type opioid receptor	GPCR	P41143	OPRD_HUMAN		Ki	7.30	PDSP
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.71	CHEMBL
Mu-type opioid receptor	GPCR		OPRM_RAT		Ki	9.66	CHEMBL
Sigma non-opioid intracellular receptor 1	Membrane other		SGMR1_CAVPO		IC50	5.68	CHEMBL
Opioid receptor	GPCR		OPRD_RAT OPRM_RAT OPRK_RAT SGMR1_RAT		Ki	10.70	CHEMBL

External reference:

ID	Source
4019936	VUID
N0000148021	NUI
D00845	KEGG_DRUG
60561-17-3	SECONDARY_CAS_RN
4019269	VANDF
4019936	VANDF
C0143993	UMLSCUI
CHEBI:9316	CHEBI
CHEMBL658	ChEMBL_ID
DB00708	DRUGBANK_ID
CHEMBL1201163	ChEMBL_ID
D017409	MESH_DESCRIPTOR_UI
41693	PUBCHEM_CID
3534	IUPHAR_LIGAND_ID
4048	INN_ID
AFE2YW0IIZ	UNII
56795	RXNORM
10199	MMSL
32203	MMSL
5519	MMSL
d00378	MMSL
001570	NDDF
004630	NDDF
370275005	SNOMEDCT_US
37527009	SNOMEDCT_US
49998007	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Sufentanil Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	0409-3382	INJECTION, SOLUTION	50 ug	EPIDURAL	ANDA	32 sections
Sufentanil Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6110	INJECTION	0.05 mg	EPIDURAL	ANDA	27 sections
Sufentanil Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6111	INJECTION	0.05 mg	EPIDURAL	ANDA	27 sections
Sufentanil Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6112	INJECTION	0.05 mg	EPIDURAL	ANDA	27 sections
Sufentanil Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	17478-050	INJECTION	50 ug	INTRAVENOUS	NDA	29 sections
Dsuvia	Human Prescription Drug Label	1	61621-430	TABLET	30 ug	SUBLINGUAL	NDA	30 sections